Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Pulmonology
•
EGPA
•
Eosinophilic granulomatosis with polyangiitis
•
Asthma
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
Do you consider benralizumab for patients with EGPA with severe pulmonary symptoms on mepolizumab?
Related Questions
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
When, if ever, would you consider methotrexate over prednisone for first line therapy in patients with pulmonary sarcoidosis?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How do you differentiate fibromuscular dysplasia from PAN / abdominal vasculitis?
Do you wait until serum anti-GBM antibody titers are undetectable before hospital discharge in a patient with anti-GBM antibody disease with renal involvement who is receiving daily plasmapheresis, cyclophosphamide, and steroids?